Literature DB >> 8982345

A modification of the N-terminal amino acid in the eremomycin aglycone.

O V Miroshnikova1, T F Berdnikova, E N Olsufyeva, A Y Pavlov, M I Reznikova, M N Preobrazhenskaya, R Ciabatti, A Malabarba, L Colombo.   

Abstract

An Edman degradation of the antibiotic eremomycin aglycone produced the corresponding hexapeptide, which was aminoacylated with D-lysine, D-histidine or D-tryptophan derivatives to give new heptapeptide analogs of the eremomycin aglycone. The aminoacylation of the eremomycin aglycone produced an octapeptide analog. The substitution of D-lysine for the N-terminal N-methyl-D-leucine does not seriously affect the in vitro antibacterial properties of the eremomycin aglycone whereas the heptapeptides with the N-terminal D-tryptophan or D-histidine moieties and the octapeptide with the N-terminal D-lysine are practically devoid of the antibacterial properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982345     DOI: 10.7164/antibiotics.49.1157

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  1 in total

1.  Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Authors:  Jan Balzarini; Els Keyaerts; Leen Vijgen; Herman Egberink; Erik De Clercq; Marc Van Ranst; Svetlana S Printsevskaya; Eugenia N Olsufyeva; Svetlana E Solovieva; Maria N Preobrazhenskaya
Journal:  Antiviral Res       Date:  2006-04-06       Impact factor: 5.970

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.